Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C-Reference-Cited by-同舟云学术

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

Published:2021-03 Issue:3 Volume:120 Page:956-964
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Hsu Shih-Jer,Yu Ming-Lung,Su Chien-Wei,Peng Cheng-Yuan,Chien Rong-Nan,Lin Hsien-Hong,Lo Gin-Ho,Su Wei-Wen,Kuo Hsing-Tao,Hsu Chao-Wei,Yang Sien-Sing,Yang Sheng-Shun,Tseng Kuan-Chiao,Qin Albert,Huang Yi-Wen,Chuang Wan-Long

Funder

PharmaEssentia Corp

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Global hepatitis report,2017

2. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection;McEwan;Value Health Reg Issues,2014

3. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience;Chen;J Infect Dis,1990

4. Genotype distribution of hepatitis C virus infection in Taiwan;Wu;J Med Virol,1994

5. The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan;Yu;Kaohsiung J Med Sci,1996

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved delivery strategies for biopharmaceuticals;Chinese Chemical Letters;2024-07

2. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19;Infectious Diseases and Therapy;2024-05-21

3. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment;Journal of the Formosan Medical Association;2024-01

4. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities;Advances in Therapy;2023-11-27

5. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera;Future Oncology;2023-04